Today we have announced that Fluicell has made significant progress in the development of a new type of catheter technology for high precision delivery of cancer therapeutics directly to tumor. Fluicell is developing this technology on behalf of the company Ambusol and has delivered key design and functionality data that advances the project toward the clinical trials that Ambusol have planned to commence in 2027.
"We are incredibly proud to be able to deliver innovative technology that contributes to the development of new cancer treatments. A key driver for us at Fluicell is that our technology is put to real use. Through the collaboration with Ambusol, we have a unique opportunity to create solutions for the benefit of patients living with severe disease. The fact that we can develop an advanced medical device from concept to functional prototype in less than a year is a clear confirmation of Fluicell's innovative ability," says Fluicell's CEO Carolina Trkulja.
On behalf of Ambusol, Fluicell is developing an advanced catheter technology with the capacity to deliver cancer drugs directly to the diseased area, with minimal systemic impact, and simultaneously remove tumor fragments and cell debris. In a first step, the technology will form part of a treatment for glioblastoma developed by Ambusol.
The collaborative project is divided into several different stages where the technology Fluicell develops needs to meet multiple pre-established functional requirements in order to advance the project to the next stage. Through the completed data delivery, the project takes an important step forward in preparation for the clinical trials that are planned to be initiated by Ambusol during 2027.
"This marks the start of the next phase in the development of our unique treatment for glioblastoma. The very promising results from previous clinical treatments give us a strong foundation to build on. With our new catheter technology, we see very good opportunities to take the next step and are now preparing together with our local partners, the phase 2-b studies that we plan to initiate in China in 2027", says Ambusol's CEO Maximilian Telander.